Advertisement
Singapore markets closed

  • Straits Times Index

    3,426.47
    -3.98 (-0.12%)
     

  • Nikkei

    37,667.41
    -202.10 (-0.53%)
     

  • Hang Seng

    17,021.31
    +16.34 (+0.10%)
     

  • FTSE 100

    8,285.71
    +99.36 (+1.21%)
     

  • Bitcoin USD

    68,009.23
    +993.79 (+1.48%)
     

  • CMC Crypto 200

    1,372.40
    +41.79 (+3.14%)
     

  • S&P 500

    5,459.10
    +59.88 (+1.11%)
     

  • Dow

    40,589.34
    +654.27 (+1.64%)
     

  • Nasdaq

    17,357.88
    +176.16 (+1.03%)
     

  • Gold

    2,385.70
    +32.20 (+1.37%)
     

  • Crude Oil

    76.44
    -1.84 (-2.35%)
     

  • 10-Yr Bond

    4.2000
    -0.0560 (-1.32%)
     

  • FTSE Bursa Malaysia

    1,612.88
    -2.30 (-0.14%)
     

  • Jakarta Composite Index

    7,288.17
    +47.89 (+0.66%)
     

  • PSE Index

    6,726.01
    +55.74 (+0.84%)
     

Why Iovance Biotherapeutics Stock Is Marching Higher Today

George Budwell, The Motley Fool
·2-min read
Why Iovance Biotherapeutics Stock Is Marching Higher Today

On a brutal day for biotech stocks, Iovance Biotherapeutics (NASDAQ: IOVA) is defying the broader trend across the space. Meanwhile, the iShares Biotechnology ETF was down by 1.6%, and the SPDR S&P Biotech ETF was in the red by 2.63% at the same point in today's trading session. While its financial results are largely immaterial at this point in its lifecycle, the company did note that it is making progress toward the possible commercial debut of lifileucel, a polyclonal tumor-infiltrating lymphocyte (TIL) therapy indicated for patients with advanced melanoma.

Continue reading